The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 780K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

35 articles for DS Karanewsky


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
26
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase EBI
Genomics Institute of The Novartis Research Foundation
10
 
Dual metalloprotease inhibitors. III. utilization of bicyclic and monocyclic diazepinone based mercaptoacetylsEBI
TBA
12
 
Dual metalloprotease inhibitors. II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetylsEBI
TBA
15
 
Dual metalloprotease inhibitors. I. constrained peptidomimetics of mercaptoacyl dipeptidesEBI
TBA
19
Discovery of GNF-5837, a Selective TRK Inhibitor with Efficacy in Rodent Cancer Tumor Models.EBI
TBA
37
Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor.EBI
Genomics Institute of The Novartis Research Foundation
25
Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.EBI
Ligand Pharmaceuticals
17
Discovery of nonsteroidal glucocorticoid receptor ligands based on 6-indole-1,2,3,4-tetrahydroquinolines.EBI
Ligand Pharmaceuticals
5
Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.EBI
Squibb Institute For Medical Research
136
Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.EBI
The Genomics Institute of The Novartis Research Foundation
56
Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.EBI
Genomics Institute of The Novartis Research Foundation
13
Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.EBI
Genomics Institute of The Novartis Research Foundation
22
Optimization of small molecule agonists of the thrombopoietin (Tpo) receptor derived from a benzo[a]carbazole hit scaffold.EBI
Genomics Institute of The Novartis Research Foundation
30
Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.EBI
Ligand Pharmaceuticals
33
5(Z)-benzylidene-1,2-dihydro-9-hydroxy-10-methoxy-2,2,4-trimethyl-5H-1-aza-6-oxa-chrysenes as non-steroidal glucocorticoid receptor modulators.EBI
Ligand Pharmaceuticals
26
Structure-activity relationships and sub-type selectivity in an oxabicyclic estrogen receptor alpha/beta agonist scaffold.EBI
Ligand Pharmaceuticals
3
Oxamyl dipeptide caspase inhibitors developed for the treatment of stroke.EBI
Idun Pharmaceuticals
19
Design, synthesis and structure-activity relationship of novel RXR-selective modulators.EBI
Ligand Pharmaceuticals
18
Design and synthesis of novel RXR-selective modulators with improved pharmacological profile.EBI
Ligand Pharmaceuticals
3
Structure-activity relationships within a series of caspase inhibitors: effect of leaving group modifications.EBI
Idun Pharmaceuticals
17
Design, synthesis, and structure-activity relationship studies of novel 6,7-locked-[7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta]-2,4,6-trienoic acids.EBI
Ligand Pharmaceuticals
18
Novel (2E,4E,6Z)-7-(2-alkoxy-3,5-dialkylbenzene)-3-methylocta-2,4,6-trienoic acid retinoid X receptor modulators are active in models of type 2 diabetes.EBI
Ligand Pharmaceuticals
20
Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.EBI
Idun Pharmaceuticals
51
Acyl dipeptides as reversible caspase inhibitors. Part 1: initial lead optimization.EBI
Idun Pharmaceuticals
10
Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.EBI
Eli Lilly
8
Vasopeptidase inhibitors: incorporation of geminal and spirocyclic substituted azepinones in mercaptoacyl dipeptides.EBI
The Bristol-Myers Squibb Pharmaceutical Research Institute
15
Conformationally constrained inhibitors of caspase-1 (interleukin-1 beta converting enzyme) and of the human CED-3 homologue caspase-3 (CPP32, apopain).EBI
Idun Pharmaceuticals
56
Discovery and Development of S6821 and S7958 as Potent TAS2R8 Antagonists.EBI
Firmenich
175
Heterocyclic Carboxylate Compounds as Glycolate Oxidase InhibitorsBDB
Lilac Therapeutics
174
Inhibitors of lysine specific demethylase-1BDB
Celgene Quanticel Research
70
Chemical compoundsBDB
AstraZeneca
9
[7,6]-fused bicyclic antidiabetic compoundsBDB
Merck Sharp & Dohme
97
Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetesBDB
Janssen Pharmaceutica
19
KCC2 POTENTIATORS AND USES THEREOFBDB
Axonis Therapeutics
29
Cyclin-dependent kinase 4 inhibitors as a treatment for cancer. Part 2: identification and optimisation of substituted 2,4-bis anilino pyrimidines.BDB
AstraZeneca